Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Sarcoma, Kaposi 1Rectal Neoplasms 1Oesophagogastric Cancer 1Non-small Cell Lung Cancer Metastatic 1Metastatic Colorectal Cancer With Left-sided Primary Tumor 1Meningeal Carcinomatosis 1HER-2 Negative Breast Cancer 1EGFR Positive Non-small Cell Lung Cancer 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Cancer Liver Metastasis 1Advanced Primary Liver Cancer 1Adenocarcinoma of Lung 1

Interventions

Nivolumab 1Ipilimumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Diabetes Mellitus, Insulin-Dependent, 12 × Bevacizumab × Clear all
NCT07128251 2025-08-17

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Anhui Provincial Hospital

Phase 2 Not yet recruiting
47 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡